Subscribe
astrazeneca-istock-458250071-fotonen-
Fotonen / iStockphoto.com
30 July 2020Big PharmaMuireann Bolger

AstraZeneca and Daiichi Sankyo to jointly develop another new cancer treatment

Biopharmaceutical company  AstraZeneca has struck a deal with Japanese pharmaceutical company  Daiichi Sankyo to jointly develop and market a new medicine to treat lung, breast and other cancers.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Daiichi and AstraZeneca fight back in cancer drug dispute with Seagen
18 November 2020   Daiichi Sankyo and AstraZeneca have asked the US District Court for the District of Delaware for a declaration that their breast cancer treatment does not infringe a chemotherapy patent owned by biotechnology company Seagen.
Americas
Seagen targets Daiichi in cancer drug suit
22 October 2020   US biotechnology company Seagen has accused Japanese pharmaceutical company Daiichi Sankyo of infringing patents with a recently-approved breast cancer drug.
Big Pharma
AstraZeneca announces new R&D, AI centres in China
11 November 2019   AstraZeneca is planning to build a new global research and development centre in China.


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025

More on this story

Americas
Daiichi and AstraZeneca fight back in cancer drug dispute with Seagen
18 November 2020   Daiichi Sankyo and AstraZeneca have asked the US District Court for the District of Delaware for a declaration that their breast cancer treatment does not infringe a chemotherapy patent owned by biotechnology company Seagen.
Americas
Seagen targets Daiichi in cancer drug suit
22 October 2020   US biotechnology company Seagen has accused Japanese pharmaceutical company Daiichi Sankyo of infringing patents with a recently-approved breast cancer drug.
Big Pharma
AstraZeneca announces new R&D, AI centres in China
11 November 2019   AstraZeneca is planning to build a new global research and development centre in China.

More on this story

Americas
Daiichi and AstraZeneca fight back in cancer drug dispute with Seagen
18 November 2020   Daiichi Sankyo and AstraZeneca have asked the US District Court for the District of Delaware for a declaration that their breast cancer treatment does not infringe a chemotherapy patent owned by biotechnology company Seagen.
Americas
Seagen targets Daiichi in cancer drug suit
22 October 2020   US biotechnology company Seagen has accused Japanese pharmaceutical company Daiichi Sankyo of infringing patents with a recently-approved breast cancer drug.
Big Pharma
AstraZeneca announces new R&D, AI centres in China
11 November 2019   AstraZeneca is planning to build a new global research and development centre in China.

More features

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims